Foghorn Therapeutics, Inc. (FHTX)
4.16
+0.02
(+0.48%)
USD |
NASDAQ |
Sep 21, 16:00
4.30
+0.14
(+3.37%)
After-Hours: 20:00
Foghorn Therapeutics Enterprise Value : 118.60M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 118.60M |
| September 17, 2026 | 122.12M |
| September 16, 2026 | 120.36M |
| September 15, 2026 | 117.42M |
| September 14, 2026 | 131.51M |
| September 11, 2026 | 135.04M |
| September 10, 2026 | 139.15M |
| September 09, 2026 | 149.72M |
| September 08, 2026 | 159.11M |
| September 04, 2026 | 164.39M |
| September 03, 2026 | 161.46M |
| September 02, 2026 | 179.07M |
| September 01, 2026 | 209.60M |
| August 31, 2026 | 212.54M |
| August 28, 2026 | 227.81M |
| August 27, 2026 | 240.72M |
| August 26, 2026 | 268.32M |
| August 25, 2026 | 277.71M |
| August 24, 2026 | 278.89M |
| August 21, 2026 | 290.63M |
| August 20, 2026 | 287.11M |
| August 19, 2026 | 290.04M |
| August 18, 2026 | 271.84M |
| August 17, 2026 | 271.25M |
| August 14, 2026 | 243.07M |
| Date | Value |
|---|---|
| August 13, 2026 | 256.58M |
| August 12, 2026 | 265.38M |
| August 11, 2026 | 262.45M |
| August 10, 2026 | 241.90M |
| August 07, 2026 | 231.92M |
| August 06, 2026 | 202.56M |
| August 05, 2026 | 162.05M |
| August 04, 2026 | 160.87M |
| August 03, 2026 | 146.19M |
| July 31, 2026 | 141.50M |
| July 30, 2026 | 153.83M |
| July 29, 2026 | 153.83M |
| July 28, 2026 | 176.72M |
| July 27, 2026 | 180.83M |
| July 24, 2026 | 160.28M |
| July 23, 2026 | 173.20M |
| July 22, 2026 | 181.42M |
| July 21, 2026 | 178.49M |
| July 20, 2026 | 180.25M |
| July 17, 2026 | 180.25M |
| July 16, 2026 | 173.20M |
| July 15, 2026 | 195.51M |
| July 14, 2026 | 191.40M |
| July 13, 2026 | 194.93M |
| July 10, 2026 | 224.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Prime Medicine, Inc. | 581.31M |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.191M |
| Revenue (Quarterly) | 16.07M |
| Total Expenses (Quarterly) | 23.26M |
| EPS Diluted (Quarterly) | -0.1018 |
| Gross Profit Margin (Quarterly) | 98.76% |
| Profit Margin (Quarterly) | -44.74% |
| Earnings Yield | -24.55% |
| Normalized Earnings Yield | -22.80 |